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Cellular processes in sepsis
Abstract
Sepsis, the systemic inflammatory response to an infection, is an increasingly common condition. It
represents a major healthcare problem as affected patients have a high morbidity and mortality leading
to high direct and indirect costs. This article describes the progression from a simple infection to septic
shock and multi-organ failure, with a special emphasis on the body's response at the cellular level.
Pathogen recognition by the host is followed by a cascade of pro- and anti-inflammatory mediators that
attempt to defend the body and prevent further harm. Both pathogen virulence and host resistance
regulate the severity of the inflammatory response. As a result of the inflammatory insult, mitochondria
are damaged functionally and structurally. Since mitochondria are responsible for intracellular energy
production, mitochondrial dysfunction places the cells at risk of developing energy failure and,
consequently, cell death. However, sepsis is characterised by a lack of tissue necrosis and the ability of
most - if not all - organs to recover completely. This underlines the assumption that organ dysfunction
during sepsis is predominantly a functional problem which appears to relate to the creation of a new
balance between energy generation and expenditure. Hence, organ dysfunction could be viewed as a
protective mechanism for the patient and may represent a state analogous to hibernation, which can be
reversed once the infection is overcome and inflammation has abated. More research is needed to
develop better directed and timed therapeutic interventions that can reduce the high morbidity and
mortality of this common condition.
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Sepsis, the systemic inflammatory response to
an infection, is an increasingly common condi-
tion. It represents a major healthcare problem as
affected patients have a high morbidity and mor-
tality leading to high direct and indirect costs.
This article describes the progression from a sim-
ple infection to septic shock and multi-organ fail-
ure, with a special emphasis on the body’s re-
sponse at the cellular level. 
Pathogen recognition by the host is followed
by a cascade of pro- and anti-inflammatory medi-
ators that attempt to defend the body and prevent
further harm. Both pathogen virulence and host
resistance regulate the severity of the inflamma-
tory response. As a result of the inflammatory in-
sult, mitochondria are damaged functionally and
structurally. Since mitochondria are responsible
for intracellular energy production, mitochondr-
ial dysfunction places the cells at risk of develop-
ing energy failure and, consequently, cell death.
However, sepsis is characterised by a lack of tissue
necrosis and the ability of most – if not all – or-
gans to recover completely. This underlines the
assumption that organ dysfunction during sepsis
is predominantly a functional problem which ap-
pears to relate to the creation of a new balance be-
tween energy generation and expenditure. Hence,
organ dysfunction could be viewed as a protective
mechanism for the patient and may represent a
state analogous to hibernation, which can be re-
versed once the infection is overcome and inflam-
mation has abated. More research is needed to de-
velop better directed and timed therapeutic inter-
ventions that can reduce the high morbidity and
mortality of this common condition.
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CD cluster of differentiation
cGMP cyclic guanosine monophosphate
DNA deoxyribonucleic acid 
IL interleukin
IRAK interleukin-1 receptor-associated kinase
LPS lipopolysaccaride (endotoxin)
MyD myeloid differentiation protein
NOD nucleotide oligomerization domain
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NRF nuclear respiration factor
PPARg peroxisome proliferator-activated receptor gamma
RNA ribonucleic acid 
TAK TRAF-associated kinase
Tfam transcription factor A
TIR toll/interleukin-1 receptor homologous region
TLR toll-like receptor
TNF tumour necrosis factor
TRAF tumour necrosis factor receptor-associated factor
Introduction
Sepsis, severe sepsis and septic shock repre-
sent increasingly grave stages of the systemic in-
flammatory response to severe infection. Such pa-
tients have a high mortality, considerable long-
term morbidity and they spend a prolonged time
in both the intensive care unit and hospital, lead-
ing to high direct and indirect costs [1]. Reported
mortality rates of 40–60% have not changed sig-
nificantly in the past 20 years despite intense re-
search and recent advances in treatment, although
the case mix has altered considerably with increas-
ing numbers of elderly and/or immunosuppressed
patients now being treated [2–4]. A recent study
from 454 German intensive care units revealed a
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sepsis prevalence of 23% [5]. The intensive care
unit and hospital mortality rates of patients with
severe sepsis (including septic shock) were 48%
and 55%, respectively.
This article describes cellular mechanisms
underlying sepsis. We highlight the progression
from a simple infection to septic shock and multi-
organ failure, with special emphasis on the body’s
response at the cellular level and with the hypoth-
esis that organ ‘failure’ may represent a protective
mechanism.
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Innate immunity and the inflammatory response to infection
Bacteria and man live, and have always lived,
in a very close, symbiotic relationship. A consider-
able number of bacteria exist on the surfaces of
every human being, predominantly in the diges-
tive tract. Not surprisingly, the skin and gut mu-
cosa are the most important barriers for prevent-
ing bacterial invasion of the human host. How-
ever, when this barrier fails or is artificially dis-
rupted (eg by burns, catheters, surgical wounds),
the host becomes susceptible to pathogen inva-
sion. The second line defence is the immune sys-
tem that can recognise, fight and destroy invading
germs. Although highly effective, the immune sys-
tem is not perfect. Both a lack of immune reaction
to a pathogen or an overwhelming immune re-
sponse will severely endanger the host. The first
situation makes the organism susceptible to infec-
tions; the latter may well destroy the pathogen but
may also severely damage the host.
Sepsis represents a systemic response of the
immune system to an infection. Both pathogen
virulence and host resistance regulate the severity
of the inflammatory response. The virulence of
the pathogen depends on the type, number and
site of invading organisms. The resistance and im-
munocompetence of the host are determined by
multiple factors including age, gender [3], genetic
predisposition [6–9], nutritional status, medica-
tions, drug/alcohol abuse, and underlying condi-
tions such as cancer or diabetes [4].
The cellular components of the innate immune system
The innate (= inborn) immune system con-
sists of humoral and cellular components. The hu-
moral component contains cytokines, chemical
substances that are directly toxic to invading mi-
crobes or that act as mediators for other cells. The
cellular component include circulating mono-
cytes, tissue macrophages, neutrophils and lym-
phocytes [10]. 
Tissue macrophages, which are derived from
blood monocytes, are capable of engulfing and di-
gesting microbes. They can also recruit other
phagocytes by secreting cytokines. Macrophages
present particles of dispatched microbes (= anti-
gens) to lymphocytes and hence interact closely
with the adaptive (= cognitive) immune system. 
Polynuclear cells include neutrophil,
eosinophil and basophil granulocytes. Neu-
trophils are important phagocytes, but can also
destroy invading pathogens by secreting toxic
substances such as reactive oxygen species [11].
Attracted by chemokines, neutrophils migrate and
translocate into the infected tissue where they
fight the pathogens [12]. The total blood neu-
trophil count may initially drop significantly dur-
ing acute infection. In response, neutrophils are
increasingly liberated from the stimulated bone
marrow, leading to a subsequent increase in the
total neutrophil count (leukocytosis). In addition,
more immature forms of neutrophils are released
from the bone marrow, which can be differenti-
ated using light microscopy (leftward shift of the
neutrophils). Eosinophil and basophil granulo-
cytes are responsible for secreting inflammatory
mediators and thereby creating an inflammatory
milieu. This leads to dilation and leakage of the
adjacent vessels, facilitating the migration of in-
flammatory cells into the infected tissue and lead-
ing to efflux of plasma. As a consequence of these
processes, clinical signs of local inflammation
occur, including redness (rubor), swelling (tumor),
increased temperature (calor) and pain (dolor). 
Importantly, cells of the innate immune sys-
tem can fight invading pathogens directly without
involvement of the adaptive immune system al-
though very close interactions exist with B and T
lymphocytes [13]. There are also important rela-
tionships with the coagulation system [14, 15] and
with other tissues such as blood vessels [16], adi-
pose tissue [17] and the gut [18]. Therefore, no
definitive answer can be given to the question as
to where, precisely, innate immunity begins and
ends [19].
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Cytokines are the humoral components of the
innate immune system and act either directly on
invading pathogens, or as mediators between cells
and organs. Reactive oxygen species in high con-
centrations have a toxic effect on bacteria by dam-
aging their cell walls. In lower concentrations,
these molecules are important regulatory media-
tors [11]. Interleukins (IL) and tumor necrosis
factor (TNF) are other mediators that have the
ability to promote inflammation from a localised
to a systemic process. Some of these cytokines are
stored in myeloid cells and are rapidly secreted
after contact with microbes. In addition, the pro-
duction of these cytokines is stimulated by com-
plex mechanisms in a time dependent manner. In
the following sections, some modes of activations
will be described. However, it is important to re-
alise that the presented schemata are markedly
simplified and not yet fully elucidated.
S W I S S  M E D  W K LY 2 0 0 8 ; 13 8 ( 4 3 – 4 4 ) : 6 2 9 – 6 3 4  ·  w w w. s m w. ch
The humoral components of the innate immune system
Pathogen recognition and activation of the inflammatory cascade
Cells of the innate immune system can detect
typical molecular patterns of most, if not all, mi-
crobes, including viruses, bacteria, fungi and pro-
tozoa. Examples of such patterns are lipopolysac-
charides (LPS, endotoxin) from the cell wall of
Gram-negative bacteria, lipoteichoic acid and
peptidoglycan from Gram-positive bacteria, un-
methylated bacterial DNA, or double-stranded
viral RNA. These non-mammalian molecules are
recognised by three families of specific pattern
recognition receptors: Toll-like receptors (TLR),
intracellular NOD proteins, and peptidoglycan
recognition proteins [10, 19]. To date ten different
types of TLR have been identified in humans [20,
21]. Most act in conjunction with other molecules
such as CD14, or with other TLRs expressed on
the cell surface. Binding of a microbial molecule
to its specific TLR results in signal transmission
by Toll/interleukin-1 receptor homologous region
(TIR) adaptor proteins to a complex intracellular
cascade of enzymes [22]. These enzymes consist of
kinases, enzymes that phosphorylate and thus ac-
tivate proteins. In the case of Gram-negative bac-
teria, LPS from the bacterial wall binds to TLR4
and CD14, activating the TIR domain called
myeloid differentiation protein (MyD)-88 (fig. 1).
This activates the interleukin-1 receptor-associ-
ated kinase (IRAK) which, in turn, stimulates the
tumour necrosis factor receptor-associated factor
(TRAF) and, consequently, the TRAF-associated
kinase (TAK) [10]. As a result, the nuclear tran-
scription factor, nuclear factor kappa B (NFkB) is
liberated from its inhibitor (IkB) and hence is able
to dislocate into the cell nucleus. The actions of
NFkB include binding to DNA, thereby activat-
ing hundreds of specific genes coding for proteins
which are increased during the inflammatory
process [23]. Although the most studied, NFkB is
only one example of many transcription factors,
that are activated during sepsis in a time-depen-
dent manner [24].
One of the genes expressed via NFkB codes
for TNF, which further amplifies local NFkB acti-
vation. On a systemic level, TNF carries the in-
flammation to other organs and, with interleukin
(IL)-6, induces the production of acute phase pro-
teins in the liver, for example, C-reactive protein
and fibrinogen. TNF also plays a very important
role in the activation of programmed cell death or
apoptosis. Another activated enzyme of major
 importance is inducible nitric oxide synthase
(iNOS). Its concentration increases after gene ac-
tivation, and its function is to generate high levels
of nitric oxide (NO), a fundamental pro-inflam-
matory molecule [25]. NO activates other en-
zymes such as guanylyl cyclase, which leads to the
production of cyclic guanosine monophosphate
(cGMP). The clinical effects of these processes
 include local and systemic vasodilation, which, if
severe, can lead to hypotension and shock. Inter-
estingly, pharmacological inhibition of both the
inducible and constitutive isoforms of the NOS
enzyme increased the blood pressure of patients
with septic shock, but had a detrimental effect on
overall survival [26–30]. This led to the assump-
tion that NO may also have beneficial effects that
are important factors in patient survival and that
total blockade of NO production or its down-
stream effects is inadvisable. 
Figure 1
Lipopolysaccharide




and CD14 on the sur-
face of immune cells.
This activates an in-
tracellular cascade,
which results in the
activation of NFkB
dependent genes
(see text for details).
It is important to re-
alise that the pre-
sented schema is
markedly simplified,
and not fully eluci-
dated.
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During sepsis, pro-inflammatory mechanisms
are heavily activated. However, anti-inflammatory
mechanisms are activated at the same time [31].
These include secretion of specific cytokines such
as IL-10 and the soluble TNF receptor and a de-
crease in the lymphocyte cell count [32]. The
overall balance is pro-inflammatory in the early
phase of sepsis and anti-inflammatory later on
[33]. The advantage of this systemic anti-inflam-
matory response may be the attenuation of dele-
terious systemic pro-inflammatory effects and the
concentration and compartmentalisation of the
inflammation at the site of infection [10]. How-
ever, when anti-inflammatory mechanisms domi-
nate, the immune system is depressed (immuno-
paresis), thus increasing the body’s susceptibility
to nosocomial infections and the reactivation of
dormant pathogens such as cytomegalovirus [34,
35]. Patients with severe sepsis might therefore
benefit from immune system stimulation [36].
However, more clinical studies are needed to con-
firm this new concept and better bedside tools are
needed to confirm timing and need for such an
intervention.
632Cellular processes in sepsis
Anti-inflammatory activity during sepsis
Microcirculation and mitochondrial dysfunction 
Early sepsis is characterised by vasodilation
and intravascular volume depletion (from in-
creased capillary leak and external losses) leading
to underfilling of the heart and a low cardiac out-
put. This is compounded by myocardial depres-
sion and potentially causes an oxygen supply-de-
mand imbalance in various organ beds [37]. Fluid
administration during early sepsis increases oxy-
gen delivery to the organs and improves clinical
outcome [38]. However, efforts to enhance oxy-
gen delivery by fluid and dobutamine administra-
tion during established sepsis with concurrent
organ failure show no benefit and may be poten-
tially harmful [39, 40]. This suggests an evolution
of the septic process and underlines the impor-
tance of optimal timing of interventions.
Alterations of the microcirculation are also
well documented in septic patients [41] and these
may decrease oxygen delivery to the tissues.
Within the cells, mitochondria require oxygen in
order to produce adenosine triphosphate (ATP)
by the process of oxidative phosphorylation. This
utilizes more than 90% of total oxygen consumed
by the body and is responsible for most of the
ATP generated by most cell types within the body,
with the neutrophil being a particular exception.
ATP is the predominant source of intracellular
energy and is needed for all energy utilizing cellu-
lar functions. Mitochondria are structurally and
functionally damaged by the inflammatory insult
following infection [42, 43]. Three separate mech-
anisms appear to cause sepsis induced mitochon-
drial dysfunction. Direct inhibition of the respira-
tory enzyme complexes can result from increased
concentrations of nitric oxide and its metabolite,
peroxynitrite. There may also be direct damage
from increased production of reactive oxygen
species. Recent studies also report genetic down
regulation of new mitochondrial protein forma-
tion [12]. This damage is facilitated by intra-mito-
chondrial defence mechanisms (reduced glu-
tathione, superoxide dismutase) being over-
whelmed [44]. 
Mitochondria are repaired or regenerated by
the process of mitochondrial biogenesis. This is
stimulated by increased expression of nuclear
transcription factors such as Tfam and NRF-1
[45, 46]. Clearly, this may prove to be a useful
strategy for accelerating organ recovery, so ap-
proaches that will stimulate biogenesis may play
an important role. NO itself is a stimulator of mi-
tochondrial biogenesis [47].
Suspended animation
Insufficient oxygen supply due to macro- and
microcirculatory failure will cause tissue hypoxia,
while impaired oxygen utilisation due to mito-
chondrial dysfunction will lead to tissue dysoxia.
Both mechanisms decrease intracellular ATP pro-
duction. This may not only impair organ specific
cell functioning, but may also result in a loss of
cell integrity, as maintenance of cellular structure
is energy-dependent. Hence, severe lack of ATP
will lead to cell dysfunction and, eventually, cell
death. One might therefore assume that organ
dysfunction is a consequence of extensive cell
death in the affected tissues and organs. However,
post mortem studies revealed little, if any, evi-
dence of cell death within dysfunctional/failed or-
gans during sepsis [48, 49]. Of note, therapeutic
options blocking apoptosis in lymphocytes were
beneficial in preclinical studies, but this has not
yet been tested in patients [50]. The lack of tissue
necrosis has led to the hypothesis that organ dys-
function might be more of a functional than struc-
tural phenomenon and thus potentially reversible.
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The cell may switch its use of ATP only to
processes essential for cell survival, such as main-
tenance of its membrane potential. By shutting
down energy-dependent organ-specific functions
the cell can decrease its total ATP expenditure, al-
lowing the net ATP balance to remain positive
despite a decrease in ATP production. This “sus-
pended animation” is analogous to aestivation and
hibernation [51, 52]. Although this is a new con-
cept for multi-organ dysfunction in sepsis, it is a
well-established protective strategy in a variety of
animals as an adaptive response to heat, cold or
drought, and it is a recognised phenomenon
within cardiomyocytes during ischaemic heart
disease and persisting hypoperfusion [53]. Hence,
organ dysfunction during sepsis could be possibly
viewed as an adaptive and potentially protective
process that will help to prevent cell death. Once
infection is overcome and more natural condi-
tions resume, mitochondrial function is restored.
ATP production then increases and the cell can
regain its normal metabolism and organ-specific
functions [33, 54].
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Sepsis is a multi-system disorder
Sepsis and its associated multi-organ dysfunc-
tion syndrome can be viewed as a vigorous re-
sponse of the host’s innate immune system to a
pathogen. However, it is increasingly clear that
this process involves the interaction of the im-
mune system with mitochondrial, endocrine, and
metabolic pathways. The response to a septic in-
sult is dynamic with distinct differences between
the acute and chronic phases of the illness. After
an initial wave of pro-inflammatory activity, a pre-
dominantly anti-inflammatory phase follows. The
initial changes are coupled with increased en-
docrine, thermogenic and metabolic activity, ex-
cessive catabolism and fuel utilisation. The later
anti-inflammatory phase is associated with declin-
ing levels of numerous hormones, bioenergetic
failure and a reduced metabolic rate. If the host
can successfully clear the infection, the resolution
of both pro- and anti-inflammatory responses will
be activated. Evidence suggests that this stage is
also highly regulated, though much more research
is needed to better understand underlying mecha-
nisms. Interestingly, most organs have the ability
to recover completely. This underlines the as-
sumption that organ dysfunction during sepsis is
not a structural problem but predominantly func-
tional and potentially reversible [55, 56].
Future perspectives
Although numerous mechanisms have been
elucidated in recent years, many important ques-
tions remain to be answered. These include the
timing and intensity of activation of both pro- and
anti-inflammatory molecules and cells and their
complex interplay with different cells and tissues.
The importance of the host’s genetic background,
age and underlying health status must be empha-
sized. There is hope for the future that specific
and timed therapeutic interventions can reduce
the high morbidity and mortality of patients with
sepsis, though there is an urgent need for bedside
biomarkers to guide these treatments. 
Conclusion
Sepsis arises if an infection progresses into a
systemic inflammatory disease. The organism will
respond to an infectious stimulus with immune
system activation, including both cellular and hu-
moral components. An initial recognition of the
pathogen is followed by a cascade of pro- and
anti-inflammatory mediators that attempt to de-
fend the body and prevent further harm.
Pathogens are able to cause mitochondrial dys-
function by causing either inhibition or damage to
the mitochondria or by having a depressant effect
on its genome. Organ dysfunction perhaps repre-
sents a protective mechanism for the patient, lead-
ing to a state of hibernation, which is reversed
once the infection is overcome. Septic mitochon-
drial damage and energy failure appears to be the
major stimulus for mitochondrial protein
turnover, a process called biogenesis. More re-
search is needed to develop specific and timed
therapeutic interventions that can reduce this
high morbidity and mortality condition. 
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